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Abstract 24 
Metastatic brain tumours represent a significant proprotion of tumours identified 25 
intraoperatively. A rapid diagnostic method, circumventing the need for histopathology 26 
studies could prove clinically useful. As many spectroscopic studies have shown ability 27 
to differentitate between different tumour types, this technique was evaluated for use 28 
within metastatic brain tumours. Spectrochemical approaches [Raman and attenuated 29 
total reflection Fourier-transform infrared spectroscopy (ATR-FTIR) spectroscopy] 30 
were applied to determine how readily it could identify the primary site from the 31 
metastatic tumour. Metastases were from primary adenocarcinomas of lung (n=7) and 32 
colorectum (n=7), and for comparison, metastatic melanoma (n=7). The objective was 33 
to determine if Raman or ATR-FTIR spectroscopy could delineate the origin of the 34 
primary tumour. The results demonstrate that there are marked similarities between the 35 
two adenocarcinoma groups and whilst Raman and ATR-FTIR can distinguish the three 36 
groups with limited success, classification accuracy is greatly improved when 37 
combining the adenocarcinoma groups. The use of such techniques in the clinical 38 
setting is more likely to be found intraoperatively, determining the presence of a tumour 39 
and suggesting the tumour class; however, traditional histopathology would still be 40 
needed to identify the primary origin of the tumour. 41 
Keywords: Attenuated total reflection Fourier-transform infrared (ATR-FTIR) 42 
spectroscopy, classification, linear discrimination analysis (LDA), metastatic brain 43 
tumour, neuro-oncology, Raman spectroscopy  44 
3 
Introduction 45 
Metastatic brain tumours are usually the end-point in a persons’ battle with cancer, 46 
yet for some may represent the initial diagnosis. The background prevalence of 47 
metastatic brain tumours is difficult to quantify; however, those clinically detectable 48 
outnumber intrinsic tumours by roughly 3 to 1, with the majority of metastases arising 49 
from primary lung tumours (Davis et. al. 2012, Huang and Ouyang 2013, Renfrow 50 
and Lesser 2013). In contrast, colorectal tumours comprise 4-8% of metastasis, yet 51 
less than 9% of all cases metastasise to the brain (Sanghvi et. al. 2017). 52 
Up to 15-25% of brain tumours diagnosed are a metastasis (Bekaert et. al. 2017). 53 
Whilst 80% of patients have a known primary, for some patients the identification of 54 
metastasis may be the initial presentation of the primary tumour (Bekaert et. al. 55 
2017). It is thought that the actual incidence of brain metastases is higher than 56 
reported as some may go undiagnosed. For those who undergo metastectomy for 57 
diagnosis or symptom relief, the tissue, once removed is sent for histopathological 58 
analysis to determine the location of the primary tumour. 59 
Currently, diagnosis generally relies upon a mix of haematoxylin and eosin (H&E) 60 
morphological appearances, special tinctorial stains and immunohistochemical (IHC) 61 
tests that enable the pathologist to give either a single or group of organs from which 62 
the primary tumour likely arises. Morphologically these tumours can look remarkably 63 
similar. However, there remains a group of unclassifiable tumours, which are labelled 64 
as ‘cancer of unknown primary (CUP)’ when histopathology and radiology fails to 65 
determine a primary origin. The challenge can then be to determine the most likely 66 
primary origin in order to guide cancer specific oncological treatment. In an era where 67 
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cancer treatment is guided more by genetic alterations, such as epidermal growth 68 
factor receptor (EGRF) mutations in lung cancer, to enable personalised treatment, the 69 
need to determine the primary origin to guide genetic testing has never been more 70 
crucial (Kalia 2015). 71 
Over recent years many biomarkers have been suggested for identification of disease 72 
and monitoring of disease progression in known cancer patients, such as prostate 73 
specific antigen (PSA) in prostate cancer patients. The difficulty, however, is that not 74 
all patients with prostate cancer will demonstrate a rise in PSA, nor do all patients 75 
with a high PSA have prostate cancer. Whilst it is thought those with prostate cancer 76 
and low PSA represents less than 1% of such patients, as the condition becomes more 77 
prevalent this is likely to increase (Lee et. al. 2010). Therefore the ability to have a 78 
specific and sensitive marker for tumours is crucial. 79 
In recent years, Raman or attenuated total reflection-Fourier transform infrared  80 
(ATR-FTIR) spectroscopy methods have been used to delineate a variety of primary 81 
and metastatic tumours with varying success (Theophilou et al. 2015, 2016). Raman 82 
and ATR-FTIR spectroscopy are complimentary techniques; Raman spectroscopy 83 
detects chemical bonds via scattering of photons due to bond vibrations, whereas 84 
ATR-FTIR spectroscopy measures energy absorbance after excitation by an infrared 85 
(IR) beam following reflection of the beam via an internal element (often diamond or 86 
germanium). Both provide a ‘fingerprint’ of the elements within the examined tissue, 87 
which have been used to differentiate between cancerous and non-cancerous tissue 88 
and biofluids within a variety of studies (Owens et. al. 2014). Krafft et al. (2006) 89 
were able to determine the primary origin from brain metastases of three tumours 90 
using IR spectroscopic imaging with variable success (Krafft et al. 2006). They 91 
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compared normal brain to metastases from lung, colon, breast and renal carcinoma. 92 
Results showed tumour primary site could be delineated; however, there was an 93 
overlap between breast, lung and colorectal carcinomas. A later study by the same 94 
group, again using imaging methods but a broader range of cancers, also 95 
demonstrated similar overlap within the adenocarcinomas (Bergner et. al. 2013). 96 
Given the relatively similar morphological appearances and IHC staining results 97 
overlaps, this is not surprising. Gajjar et. al. (2012) also demonstrated positive results 98 
in distinguishing different intrinsic brain tumours from normal brain tissue, 99 
demonstrating the ability of Raman and ATR-FTIR spectroscopy to segregate 100 
different tumour types (Gajjar et. al. 2012). 101 
Outside of the brain, the use of spectroscopy on both tissue and blood components has 102 
shown promise in the detection of many cancers around the body, including skin, 103 
oesophagus, ovary and cervix with varying degrees of success (Krafft et. al. 2006, 104 
Gajjar et. al. 2012, Lyng et. al. 2007, Lui et. al. 2012, Kendall et. al. 2010, Barr et. al. 105 
2011, Mitchell et. al. 2014). However, relatively few studies focus on the 106 
differentiation of primary tumour from metastasis. Therefore, within this study, brain 107 
metastasis from lung and colorectal adenocarcinomas have been chosen due to their 108 
similar morphological appearances (see Figure 1), and their ability to often have 109 
challengingly similar IHC staining patterns. Whilst at first glance these tumours may 110 
appear different, it is not possible on morphology alone to determine the definitive 111 
primary location of the tumour and immunohistochemistry is regularly performed. 112 
This limited variability between the two adenocarcinomas will provide a challenge to 113 
determine if Raman and/or ATR-FTIR spectroscopy can detect these differences and 114 
indicate tumour origin. To contrast this, metastatic melanoma was selected since it 115 
provides a marked contrast in both appearances and immunohistochemical staining 116 
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patterns to the adenocarcinomas (see Figure 1). The initial hypothesis was that the 117 
two adenocarcinoma groups would show similar spectral patterns and therefore would 118 
be difficult to differentiate as compared to the metastatic melanoma group, which 119 
would demonstrate a marked difference. The novelty of this study lies in the 120 
comparison of both Raman and FTIR-ATR within a pre-selected group of metastases, 121 
with the analyses performed on spectral analysis without the need for complex 122 
imaging. 123 
Methods 124 
Formalin-fixed paraffin embedded tissue from twenty-one brain metastasis 125 
comprising colorectal adenocarcinoma metastasis (n=7), lung adenocarcinomas 126 
metastasis (n=7) and metastatic melanomas (n=7) were obtained from the Brain 127 
Tumour North West (BTNW) research tissue bank (RTB – ethics NRES14/EE/1270). 128 
Sections (10-μm-thick) were placed onto glass slides covered with aluminium foil.  129 
Foil-covered slides have been previously demonstrated to be as effective as more 130 
expensive substrates significantly reducing the costs of this process (Cui et. al. 2016; 131 
Paraskevaidi et al. 2018). These were de-waxed prior to spectral acquisition by 132 
leaving overnight in fresh xylene. They were then washed in fresh xylene for 5 min. 133 
Following this, they were immersed in fresh ethanol at 100% twice and then 70% 134 
ethanol once, for 5 min each, and then allowed to air dry prior to spectral acquisition. 135 
H&E-stained slides were viewed to delineate the tumour to be examined, to reduce 136 
contamination of spectra from background brain tissue. 137 
 138 
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Raman spectroscopy 139 
A Renishaw InVia Raman spectrometer was used to collect 25 spectra per section 140 
using a 785 nm laser at 1200 g mm-1 grating with an acquisition time of 30 seconds 141 
for each sample. This was over a spectral range of 400-1600 cm-1. A 50× objective 142 
with numerical aperture of 0.85 was used to focus the laser beam. The spectral sites 143 
were selected at random moving over the tissue. 144 
Attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy 145 
ATR-FTIR spectra were collected using a Bruker Tensor 27 Fourier transform 146 
infrared spectrometer with Helios attenuated total reflection attachment containing a 147 
diamond crystal internal reflective element and a 45° incidence angle of infrared 148 
beam. A new background spectrum was collected prior to each new sample, following 149 
cleaning of the crystal with distilled water. For each case 32 scans with 8 cm-1 150 
spectral resolution were taken at 10 randomly selected points. The sampling aperture 151 
was 250 μm × 250 μm and the mirror velocity was 2.2 Hz. 152 
Computational analyses 153 
Computational analyses, including principal component analysis (PCA) with linear 154 
discriminant analysis (LDA) and linear discriminant classifier (LDC) was then 155 
performed within a MATLAB (Mathworks, Natick, USA) environment, using the 156 
IRootlab toolkit as a user interface (Martin et al. 2010, Trevisan et. al. 2013, 157 
Paraskevaidi et al. 2017). For classification spectra were pre-processed by cutting to 158 
the region of interest (Raman = 500-1800 cm-1; ATR-FTIR = 900-1800 cm-1), 159 
followed by polynomial baseline correction and vector normalisation. Spectra were 160 
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then interrogated via PCA-LDA to generate scores plots and cluster vectors to 161 
determine points of variation between the spectra; PCA-LDC was then applied to 162 
calculate the classification accuracy as compared to the histopathological result. The 163 
top 6 spectral differences between the adenocarcinoma and melanoma groups were 164 
also determined. 165 
Results 166 
Analysis of the spectra has shown similar results for both Raman and ATR-FTIR 167 
spectroscopy. They demonstrate similar spectral appearances for both 168 
adenocarcinoma groups, with significant differences seen to the spectra of the 169 
melanoma. This can be seen primarily within both the pre-processed spectra [see 170 
Figure 2]. The lines for both adenocarcinoma groups show little variance, with the 171 
melanoma line clearly being separated at several points. 172 
PCA-LDA was carried out to determine the principal components and thus the factors 173 
that account for most variance between the three groups in order to classify them. It 174 
was demonstrated that the groups show a degree of overlap (see Figure 3), which is 175 
greatest between the two adenocarcinoma groups. The points within the clusters show 176 
little difference within the adenocarcinoma groups, thought the melanoma group is 177 
clearly separated, with little overlap of the confidence bubbles. From this, cluster 178 
vectors were used to visualise the differences between the three groups. It can be seen 179 
(Figure 4) that the two adenocarcinoma groups are similar with small areas of 180 
variance (Figure 4 D/d) as the lines are almost superimposed upon each other. 181 
However, the melanoma groups show a marked difference, with much greater 182 
separation of the two lines. This is particularly demonstrated within panel (D/d) where 183 
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melanoma is taken as the baseline. This shows how similar adenocarcinomas are 184 
despite their different primary locations. 185 
A PCA-LDC, giving the classification accuracy for each group as compared to the 186 
final histological diagnosis, was then performed (Figure 5). This was run for three 187 
separate groups and then two (combining the two adenocarcinoma groups) groups to 188 
show the difficulty in separating the adenocarcinomas. When using three groups for 189 
Raman, the classification accuracy is 69% for colorectal adenocarcinoma, 69% for 190 
lung adenocarcinoma and 72% for melanoma. Using ATR-FTIR spectroscopy this is 191 
60% for colorectal adenocarcinoma, 59% for lung adenocarcinoma and 47% for 192 
melanoma. If the two adenocarcinoma groups are combined, classification accuracy 193 
markedly increases. With Raman spectroscopy this improves to 85% for 194 
adenocarcinoma and 75.4% for melanoma, and with ATR-FTIR spectroscopy 96% 195 
for adenocarcinoma and 72% for melanoma. This is, however, still below that found 196 
with traditional histopathology. 197 
Following this, a one-way Anova was performed for the three groups to assess if the 198 
differences seen between the spectra were significant. A student’s t-test was 199 
performed on the merged 2 groups to assess significance due to the small numbers 200 
involved (Figure 6). This was performed on the PCA-LDA results using all spectra 201 
for each case. For the three Raman spectroscopy groups this was P=0.0016 at 95% 202 
confidence interval and for ATR-FTIR spectroscopy this was not significant (P=0.08) 203 
[see Supplementary information (SI) Table S1]. For two groups, this was again 204 
significant at <0.0001 for Raman and ATR-FTIR, with a 95% confidence interval (see 205 
SI Table S2). 206 
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The statistical significance between each group was also calculated using a one-way 207 
Anova (see SI Table S1). This highlights the statistically significant differences found 208 
between adenocarcinoma and melanoma. There is no statistical difference between 209 
the two adenocarcinoma groups on either Raman or ATR-FTIR spectroscopy. 210 
To conclude, the significant differences were calculated (see Figure 7) and tentative 211 
distinguishing wavenumbers assigned to those differences (Table 1). This was done to 212 
examine the points at which the tumours vary and to see which areas accounted for 213 
the variation. Within both Raman and ATR-FTIR spectroscopy the main variances 214 
were found within CH2 bond deformation and methylene twisting regions. Changes 215 
within these regions have previously been reported within carcinogenic samples 216 
(Movasaghi, Rehman and Rehman 2007, 2008) of varying types. Therefore, perhaps 217 
these regions are tied to carcinogenesis and not the particular tumour type with 218 
variations seen depending on the tumour.  219 
Discussion 220 
Both spectroscopic methods have been shown to be able to classify the different 221 
tumours by type (i.e., adenocarcinoma vs. melanoma), providing similar results. 222 
However, accuracy is greatly diminished if it is used to classify the primary origin of 223 
the tumour type, specifically determining if the adenocarcinoma arose within the lung 224 
or colon. Minor differences are seen between the spectra of these two tumours (see 225 
Figure 2); however, these differences are not statistically significant. This would, 226 
therefore, limit any clinical use, as it would not be able to provide as much 227 
information as traditional histopathology with H&E and IHC. It may be that such new 228 
tools may aid the clinician in determining tumour type intra-operatively, i.e. that the 229 
tumour is a metastasis and not a primary brain tumour, but formal histopathology with 230 
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IHC would still be required for primary tissue origin identification. This, however, is 231 
also of interest given the marked spectral similarities between adenocarcinomas of 232 
different primary origins (Figures 2 and 4). Within this study, confounding factors, 233 
such as the number or location of the brain metastasis, nor patient factors have been 234 
used to contribute to the accuracy of the results. As this was a comparison to 235 
conventional histopathology, these factors would not impact upon microscopy or 236 
immunohistochemistry, therefore it was felt not appropriate to be added into the 237 
diagnostic algorithm. 238 
When evaluating the potential value of spectroscopy as a possible intraoperative tool 239 
its ability to determine cancer versus no cancer and suggest a tumour type would be 240 
required. To provide further information to that provided by intraoperative 241 
neuropathology, spectroscopy would need to differentiate the primary tumour origin 242 
for a metastasis. However, as can be seen, both Raman and ATR-FTIR spectroscopy 243 
are able to detect differences between the two tumour types, but not specify the 244 
primary tissue origin accurately enough for treatment decisions. As the technique 245 
develops, it may replace frozen section, often performed intraoperatively to determine 246 
if a tumour is primary, i.e., has arisen within the brain, or is a metastasis to guide the 247 
surgeon in relation to the extent of the resection he may perform, as has been 248 
suggested previously (Ji et. al. 2013, Ji et. al. 2015, Hollon et. al. 2016).  At which 249 
point, acknowledgement of a metastasis (from a primary tumour) would be the level 250 
required with histopathology completing the primary tumour origin determination as 251 
currently occurs. This would provide a potentially useful area for the technology to 252 
exploit as frozen section work can be challenging and potentially an area for error to 253 
be removed by use of spectroscopy. However, comparative work to normal brain 254 
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tissue and primary tumours would be required to ensure the technique is able to 255 
differentiate all potential results. 256 
 257 
Conclusion 258 
 259 
This study has highlighted both forms of spectroscopy are able to differentiate 260 
different tumour types such as melanoma versus adenocarcinoma. However, it is not 261 
able to differentiate tumour types to determine primary tissue origin of a metastasis in 262 
its current form.  263 
As the technique develops, it may eventually be able to provide additional 264 
information to support the initial histopathological diagnosis, which may in the future 265 
provide treatment related or prognostic information once the spectra are fully 266 
understood in the years to come. 267 
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Table 1 The tentative assignments of significant points of difference for Raman and 377 
attenuated total reflection-Fourier transform infrared (ATR-FTIR) spectroscopy, 378 
using adenocarcinoma vs. melanoma (Movasaghi, Rehman and Rehman 2007, 2008). 379 
Method Wavenumber (cm-1) Tentative assignment 
Raman  1310 
CH3/CH2 twisting or bending mode of lipid/collagen 
CH3/CH2 twisting, wagging &/or bending mode of 
collagens & lipids 
 1297 CH2 deformation/Palmitic acid, acyl chains, fatty acids 
 1296 CH2 deformation 
 1295 Methylene twisting /CH2 deformation 
 1294 Methylene twisting 
 1293 Cytosine/ Methylene twisting 
ATR-
FTIR 
1720 C=O 
 1578 Ring C-C stretch of phenyl 
 1481 Amide II 
 1477 CH2 bending of methylene chains in lipids 
/Polyethylene methylene of deformation modes 
 1474 CH2 bending of methylene chains in lipids 
/Polyethylene methylene of deformation modes 
 1470 CH2 bending of methylene chains in lipids 
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 380 
Figure 1 Representative photomicrographs of the microscopic appearance of brain 381 
metastasis from different primary tumour sites. (A) is a metastasis from a colorectal 382 
adenocarcinoma (H&E ×200 objective); (B) is a metastasis from a lung 383 
adenocarcinoma (H&E ×200 objective); and, (C) is a metastasis from a malignant 384 
melanoma (H&E ×200 objective). 385 
  386 
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 387 
Figure 2 A graph demonstrating the mean pre-processed spectra from each tumour 388 
group using: (A) Raman spectroscopy (cut to the region of interest, polynomial 389 
baseline correction and vector normalisation); and, (B) ATR-FTIR spectroscopy (cut 390 
to the region of interest, rubberband baseline correction and vector normalisation). 391 
(KEY: CA=COLORECTAL ADENOCARCINOMA, LA=LUNG ADENOCARCINOMA, 392 
MM=MELANOMA). 393 
 394 
  395 
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 397 
Figure 3 A graph demonstrating the PCA-LDA results for Raman and ATR-FTIR 398 
spectroscopy. The left side demonstrates the Raman spectroscopy results firstly 399 
without (A) and secondly with (B) 95% confidence intervals. This is then mirrored on 400 
the right for ATR-FTIR spectroscopy, without (C) and with (D) 95% confidence 401 
intervals. (KEY: CA – COLORECTAL ADENOCARCINOMA, LA – LUNG 402 
ADENOCARCINOMA, MM – MALIGNANT MELANOMA) 403 
 404 
 405 
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 407 
Figure 4 These graphs show the cluster vectors for Raman and ATR-FTIR 408 
spectroscopy. The upper case displays the Raman spectroscopy results, starting 409 
with (A/a) all the groups, (B/b) CA is taken as the baseline, (C/c) LA taken as 410 
the baseline, (D/d) MM taken as baseline and (E/e) compares adenocarcinoma 411 
22 
vs. MM. This is mirrored on the right, with lower case letters for ATR-FTIR 412 
spectroscopy. (KEY: CA – COLORECTAL ADENOCARCINOMA, LA – LUNG 413 
ADENOCARCINOMA, MM – MALIGNANT MELANOMA, ADCA – 414 
ADENOCARCINOMA). 415 
  416 
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Figure 5 The confusion matrices display the percentage of the results assigned to the 418 
correct group (green) or another group (red). The Raman results are shown on the left 419 
with (A) displaying each of the three cancer groups separately, and (B) compares 420 
adenocarcinoma to MM. On the right are the ATR-FTIR spectroscopy results; (C) 421 
displays each of the three cancer groups separately and (D) again compares 422 
adenocarcinoma to MM. (KEY: CA – COLORECTAL ADENOCARCINOMA, LA – 423 
LUNG ADENOCARCINOMA, MM – MALIGNANT MELANOMA, ADCA – 424 
ADENOCARCINOMA). 425 
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Figure 6 These graphs represent the results of both a one-way Anova and student’s t-427 
test scores plot for Raman and ATR-FTIR spectroscopy. (A) shows the one-way 428 
Anova for Raman with all three tumour groups, (B) the student’s t-test for Raman 429 
spectroscopy with adenocarcinoma and MM. This is mirrored for ATR-FTIR 430 
spectroscopy with (C) showing the one-way Anova for ATR-FTIR spectroscopy with 431 
all three tumour groups and (D) the student’s t-test for ATR-FTIR spectroscopy with 432 
adenocarcinoma and MM. (KEY: CA – COLORECTAL ADENOCARCINOMA, LA – 433 
LUNG ADENOCARCINOMA, MM – MALIGNANT MELANOMA). 434 
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Figure 7 The significant wavenumber differences between the adenocarcinoma 436 
groups and melanoma. (A): Raman spectroscopy, (B): ATR-FTIR spectroscopy 437 
